Azoles (local routes only) updated on 01-29-2025

Major congenital malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17614
R74400		 Araujo - Sertaconazole (Topical), 2022 Major congenital anomalies overall 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Route of exposure Azoles: Dermal/Topical 1.01 [0.84;1.21] -/-   -/91,976 - -
ref
S4170
R9628		 Rotem - Clotrimazole (Vaginal), 2018 Major malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Route of exposure Azoles: Vaginal 1.11 [0.93;1.33] 134/1,993   5,777/95,781 5,911 1,993
ref
S17524
R73714		 Czeizel - Clotrimazole, 1999 Congenital abnormalities (excluding infants with three mild defects (congenital dislocation of hip based on Ortolani click, congenital inguinal hernia, and hemangiomas), syndromes of known origin (eg, chromosome disorders), and minor anomalies) 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Matched Route of exposure Azoles: Local (NOS) 0.95 [0.79;1.14] 253/751   18,262/50,568 18,515 751
ref
S4260
R9862		 Jick - Azole (Topical route), 1999 Congenital anomaly 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Route of exposure Azoles: Local (NOS) 0.60 [0.20;1.60] 5/492   26/1,629 31 492
ref
Total 4 studies 1.02 [0.92;1.13] 24,457 3,236
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Araujo - Sertaconazole (Topical), 2022Araujo - Sertaconazole, 2022 1 1.01[0.84; 1.21]--33%ROB confusion: unclearROB selection: lowROB classification: criticalROB missing: unclearROB mesure: unclearROB reporting: moderate Rotem - Clotrimazole (Vaginal), 2018Rotem - Clotrimazole, 2018 2 1.11[0.93; 1.33]5,9111,99334%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Czeizel - Clotrimazole, 1999Czeizel - Clotrimazole, 1999 0.95[0.79; 1.14]18,51575132%ROB confusion: unclearROB selection: criticalROB classification: moderateROB missing: moderateROB mesure: criticalROB reporting: moderate Jick - Azole (Topical route), 1999Jick - Azole, 1999 3 0.60[0.20; 1.60]314921%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Total (4 studies) I2 = 0% 1.02[0.92; 1.13]24,4573,2360.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topical; 2: Vaginal; 3: Topical route;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.05[0.93; 1.19]5,9422,4850%NAAraujo - Sertaconazole (Topical), 2022 Rotem - Clotrimazole (Vaginal), 2018 Jick - Azole (Topical route), 1999 3 case control studiescase control studies 0.95[0.79; 1.14]18,515751 -NACzeizel - Clotrimazole, 1999 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.02[0.92; 1.13]24,4573,2360%NAAraujo - Sertaconazole (Topical), 2022 Rotem - Clotrimazole (Vaginal), 2018 Czeizel - Clotrimazole, 1999 Jick - Azole (Topical route), 1999 4 Tags Adjustment   - No  - No 0.60[0.21; 1.70]31492 -NAJick - Azole (Topical route), 1999 1   - Yes  - Yes 1.02[0.92; 1.14]24,4262,7440%NAAraujo - Sertaconazole (Topical), 2022 Rotem - Clotrimazole (Vaginal), 2018 Czeizel - Clotrimazole, 1999 3 MatchedMatched 0.95[0.79; 1.14]18,515751 -NACzeizel - Clotrimazole, 1999 1 Route of exposure Azoles   - Dermal/Topical  - Dermal/Topical 1.01[0.84; 1.21]-- -NAAraujo - Sertaconazole (Topical), 2022 1   - Local (NOS)  - Local (NOS) 0.94[0.78; 1.12]18,5461,2430%NACzeizel - Clotrimazole, 1999 Jick - Azole (Topical route), 1999 2   - Vaginal  - Vaginal 1.11[0.93; 1.33]5,9111,993 -NARotem - Clotrimazole (Vaginal), 2018 1 All studiesAll studies 1.02[0.92; 1.13]24,4573,2360%NAAraujo - Sertaconazole (Topical), 2022 Rotem - Clotrimazole (Vaginal), 2018 Czeizel - Clotrimazole, 1999 Jick - Azole (Topical route), 1999 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.21.30.6370.000Araujo - Sertaconazole (Topical), 2022Rotem - Clotrimazole (Vaginal), 2018Czeizel - Clotrimazole, 1999Jick - Azole (Topical route), 1999

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.02[0.92; 1.13]24,4573,2360%NAAraujo - Sertaconazole (Topical), 2022 Rotem - Clotrimazole (Vaginal), 2018 Czeizel - Clotrimazole, 1999 Jick - Azole (Topical route), 1999 40.510.01.0